European Business Summits
info@ebsummit.eu – 0032 (0) 2 645 34 80
TRANSPARENCY REGISTER 268958411031-65
PRIVACY-POLICY | GENERAL TERMS OF SALES
Partners
ABOUT
The EHS Task Force has been set up due to the considerable success with the launching of the European Health Summit last December in 2020. This platform has been designed to drive policy in the domain of health, aside from organizing high-level annual events.
The aim is not only to create a larger healthcare network and provide visibility, but also to be able to steer the process of policy making at the European level and strengthen the link between public and private partnership through the involvement of cross-sectorial stakeholders.
PROGRAMME OF 2021
30 March 2021
WORKING GROUP 1 (CLOSED MEETING): Pandemics and vaccines, HERA Incubator
23 April 2021
EHS TASK FORCE PUBLIC DEBATE: PANDEMICS AND VACCINES, HERA INCUBATOR
Pierre Delsaux
DG SANTÉ, European Commission
Deputy Director General
Mehreen Khan
Financial Times Brussels Correspondent
Michel Goldman
I3h Institute, ULB
President
Maria Carvalho
Member of the European Parliament
Luc Debruyne
Strategy Advisor to CEO, CEPI
Former CEO, GSK Vaccines
Heike Galbraith
Pfizer
Global Director rare diseases and vaccines
Sam Proesmans
Advisor to the Belgian Prime Minister
Elena Bonfiglioli
Microsoft
Regional business leader health and life sciences EMEA
What is Europe’s strategy in combating COVID-19 strains?
The first public event of the EHS Task Force will debate the Commission’s work on emergency preparedness and the EU’s capacity to swiftly secure access to the necessary vaccines, whenever needed. Join our discussion on HERA (European Health Emergency Preparedness and Response Authority) Incubator.
11 May 2021
WORKING GROUP 2 (CLOSED MEETING): EUROPEAN HEALTH DATA SPACE (USE OF RWD data, validating use of secondary data)
8 June 2021
Working group 3 (CLOSED MEETING): rare diseases, advanced therapies
10 June 2021
EHS Task Force PUBLIC DEBATE – EUROPEAN HEALTH DATA SPACE
Petra De Sutter
Belgian Deputy P.M. and Minister of Civil Service, Public Enterprises, Telecommunications & Post
Mario Campolargo,
Director-General DIGIT, European Commission
Bert Verdonck
Program Manager Health Data Initiatives and GAIA-X, Philips
Elena Bonfiglioli
Regional business leader health and life sciences EMEA, Microsoft
Menno Kok
Managing director EIT Health Belgium – Netherlands
John Gordon
Sr. Director, Innovation Lab Lead, International Developed Markets (IDM), Pfizer Digital
Thomas Kostera
Senior Expert, Bertelsmann Stiftung
Arnaud Thysen
EBS Director General
Building a home for health data in Europe
In order to position itself as a global leader in health and innovation, the European Union needs a secure, transparent and sovereign framework for data. Although sharing data is imminent to achieve the aforementioned, it also raises ethical, technical and security challenges. How to unlock the prospects of a European Health Data Space and how can these issues be dealt with? What should be the next steps and who should be involved?
8 July 2021
EHS Task Force PUBLIC debate: rare diseases, advanced therapies - wıth the focus on gene therapy
Michel Goldman
I3h Institute, ULB
President
Kaja Kantorska
DG SANTE, European Commission
Policy Officer Pharmaceuticals
Simone Boselli
EURORDIS
Public Affairs Director
Prof. Hildegard Büning
European Society of Gene and Cell Therapy
President
Irene Norstedt
DG RTD, European Commission
Deputy Head of Unit Personalised Medicine
Dirk Vander Mijnsbrugge
Pfizer
Vice President, Medical Affairs Lead Rare Diseases
Brieuc Van Damme
RIZIV-INAMI
Director-General Healthcare
Arnaud Thysen
EBS Director General
The potential of advanced therapies is groundbreaking for patients suffering from rare diseases. The boundaries of research have shifted significantly over the past years. Innovation has reached new heights. It challenges the classic model of regulation, healthcare policies and drug development. The debate will touch upon the prospects of advanced therapies, their implications for public health and cross sectoral collaboration. The aim? Securing an accessible, affordable and safe product for physicians and patients across Europe.
September 2021
Working Group 4 (CLOSED MEETING): HERA STATUS
October 2021
EHS Task Force PUBLIC debate: HERA STATUS
Have a question? Contact our team!
